| Dr Sandra Ana Antonovic, MD | |
|
12442 Sw Scholls Ferry Rd, Suite 205, Tigard, OR 97223-0804 | |
| (503) 216-9140 | |
| (503) 216-9145 |
| Full Name | Dr Sandra Ana Antonovic |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 12442 Sw Scholls Ferry Rd, Tigard, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184773319 | NPI | - | NPPES |
| 272420 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD23792 (Oregon) | Primary |
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.
Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.
A new statement from American and European cardiology experts advises heart patients and their partners to receive individually tailored counseling from healthcare professionals about resuming sexual activity.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sandra Ana Antonovic, MD Po Box 3158, Portland, OR 97208-3158 Ph: () - | Dr Sandra Ana Antonovic, MD 12442 Sw Scholls Ferry Rd, Suite 205, Tigard, OR 97223-0804 Ph: (503) 216-9140 |
News Archive
Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.
Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.
A new statement from American and European cardiology experts advises heart patients and their partners to receive individually tailored counseling from healthcare professionals about resuming sexual activity.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.
› Verified 1 days ago
Margaret Allison Baynham, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7213 Sw Hazelfern Rd, Tigard, OR 97224 Phone: 503-214-2064 Fax: 503-598-3600 | |
Leila Hotaki Mesch, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12442 Sw Scholls Ferry Rd Ste 205, Tigard, OR 97223 Phone: 503-216-9140 | |
Kirsten Crowley, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 12442 Sw Scholls Ferry Rd, Suite 205, Tigard, OR 97223 Phone: 503-216-9140 Fax: 503-216-9145 | |
Carol Lynn Schriner, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9250 Sw Hall Blvd, Tigard, OR 97223 Phone: 503-293-0161 Fax: 503-221-4451 | |
Dr. Zaid Saad Al-mulla, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9735 Sw Shady Ln Ste 300, Tigard, OR 97223 Phone: 503-466-1779 Fax: 503-598-9030 | |
Sarah A Leffler Wagoner, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 12442 Sw Scholls Ferry Rd Ste 205, Tigard, OR 97223 Phone: 503-216-9140 |